Currency In USD
| Previous Close | 0.4 |
| Open | 0.41 |
| Day High | 0.42 |
| Day Low | 0.37 |
| 52-Week High | 2.38 |
| 52-Week Low | 0.27 |
| Volume | 186,167.86 |
| Average Volume | 660,050 |
| Market Cap | 18.12M |
| PE | -0.3 |
| EPS | -1.24 |
| Moving Average 50 Days | 0.46 |
| Moving Average 200 Days | 0.86 |
| Change | -0.03 |
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
GlobeNewswire Inc.
Feb 24, 2026 9:09 PM GMT
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immu
Werewolf Therapeutics Announces Pipeline and Business Updates
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profileWTX-330 Phase 1b/2 tria
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mous